Apellis Pharmaceuticals, Inc. (APLS) Tops Q3 EPS by 12c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of $1.67, $0.12 better than the analyst estimate of $1.55. Revenue for the quarter came in at $458.6 million versus the consensus estimate of $450.97 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Morgan Stanley Downgrades Repsol SA (REP:SM) (REPYY) to Equalweight
• Crusoe in talks to raise $3B in funding - Bloomberg